<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04682340</url>
  </required_header>
  <id_info>
    <org_study_id>BPA-Thyroid</org_study_id>
    <nct_id>NCT04682340</nct_id>
  </id_info>
  <brief_title>Analysis of BPA Concentration in Serum in Women of Reproductive Age With Autoimmune Thyroid Disease</brief_title>
  <official_title>Analysis of Bisphenol A Concentration in Serum in Women of Reproductive Age With Autoimmune Thyroid Disease</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Jagiellonian University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Jagiellonian University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The aim of the study is to assess the relationship between the concentration of bisphenol A&#xD;
      in serum and selected parameters of thyroid function in women of reproductive age with&#xD;
      thyroid dysfunction - Hashimoto's disease and Graves' disease.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">December 22, 2020</start_date>
  <completion_date type="Anticipated">October 30, 2021</completion_date>
  <primary_completion_date type="Anticipated">August 30, 2021</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Control</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Comparison of serum BPA levels between the group with AITD and control group</measure>
    <time_frame>Dec 2020 - April 2021</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>The association between serum BPA levels and serum thyroid hormone levels in the AITD group</measure>
    <time_frame>Dec 2020 - April 2021</time_frame>
    <description>To determine the association between serum BPA concentrations and serum thyroid hormone levels in adult women</description>
  </secondary_outcome>
  <number_of_groups>3</number_of_groups>
  <enrollment type="Anticipated">80</enrollment>
  <condition>Hypothyroidism</condition>
  <condition>Hyperthyroidism</condition>
  <condition>Hashimoto Disease</condition>
  <condition>Graves Disease</condition>
  <arm_group>
    <arm_group_label>Hashimoto's Group</arm_group_label>
    <description>Thyroid antibody positive and hypothyroidism</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Graves' Group</arm_group_label>
    <description>Thyroid antibody positive and hyperthyroidism</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control Group</arm_group_label>
    <description>Thyroid antibody negative and euthyroidism</description>
  </arm_group>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>Serum BPA</intervention_name>
    <description>Serum BPA levels will be compared between women with autoimmune thyroid disease and normal women.</description>
    <arm_group_label>Control Group</arm_group_label>
    <arm_group_label>Graves' Group</arm_group_label>
    <arm_group_label>Hashimoto's Group</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Women in the reproductive age from 18 to 45 years of age will be qualified to the study&#xD;
        group. Women will be recruited from among patients admitted to the University Hospital in&#xD;
        Krakow. After qualifying for the study, each patient will be collected demographic data,&#xD;
        information about medical history and medications, as well as anthropometric data.During&#xD;
        the medical visit, patients will be presented with all information about participation in&#xD;
        the study and only those who give their informed consent in writing will be qualified for&#xD;
        the study. Based on the clinical picture and the results of laboratory tests (the level of&#xD;
        TSH, fT4 in the plasma and the presence of thyroid autoantibodies), the patients will be&#xD;
        divided into 2 groups - 30 women with hyperthyroidism, 30 women with hypothyroidism. 20&#xD;
        healthy women without any thyroid dysfunction will be the control group. The groups will be&#xD;
        matched according to age, body mass index and smoking.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Graves' disease or Hashimoto's disease (positive thyroid autoantibody)&#xD;
&#xD;
          -  Control group: thyroid autoantibody negative, normal thyroid function&#xD;
&#xD;
          -  Women aged 18 to 45 in both the control group and experimental group&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Pregnancy and lactating women&#xD;
&#xD;
          -  Previous or planned treatment with 131I or thyroidectomy&#xD;
&#xD;
          -  The use of drugs affecting the thyroid function (lithium, amiodarone, interferon a,&#xD;
             sodium nitroprusside, sunitinib, sorafenib, iodine contrast, antibiotics / antifungals&#xD;
             / antivirals (for at least 4 weeks prior to recruitment to the study), which do not&#xD;
             result from the treatment of thyroid disease (levothyroxine, thyreostatic drugs,&#xD;
             glucocorticoids)&#xD;
&#xD;
          -  Active malignancy&#xD;
&#xD;
          -  Other autoimmune diseases&#xD;
&#xD;
          -  Other endocrine diseases&#xD;
&#xD;
          -  Patients with severe liver, kidney or heart failure&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Karolina Zawadzka</last_name>
    <phone>792916751</phone>
    <email>karolina.zawadzka@onet.pl</email>
  </overall_contact>
  <location>
    <facility>
      <name>Jagiellonian University Medical College</name>
      <address>
        <city>Krak√≥w</city>
        <state>Malopolska</state>
        <zip>31-591</zip>
        <country>Poland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Karolina Zawadzka</last_name>
      <phone>792916751</phone>
      <email>karolina.zawadzka@onet.pl</email>
    </contact>
  </location>
  <location_countries>
    <country>Poland</country>
  </location_countries>
  <verification_date>June 2021</verification_date>
  <study_first_submitted>December 13, 2020</study_first_submitted>
  <study_first_submitted_qc>December 18, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">December 23, 2020</study_first_posted>
  <last_update_submitted>June 15, 2021</last_update_submitted>
  <last_update_submitted_qc>June 15, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">June 18, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Jagiellonian University</investigator_affiliation>
    <investigator_full_name>Karolina Zawadzka</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <keyword>bisphenol A</keyword>
  <keyword>BPA</keyword>
  <keyword>Hashimoto's Disease</keyword>
  <keyword>Graves' Disease</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Graves Disease</mesh_term>
    <mesh_term>Hypothyroidism</mesh_term>
    <mesh_term>Thyroid Diseases</mesh_term>
    <mesh_term>Hyperthyroidism</mesh_term>
    <mesh_term>Hashimoto Disease</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

